AGM 2023 Presentation

November 29, 2023March 10, 2025 Alterity Therapeutics

2023

Post navigation

Alterity Therapeutics Prominently Featured at the International MSA Congress
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

AGM 2023 Presentation

Related Posts

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

XBRL 30 June 2024 filed with the SEC

European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial